A tighter archive for life-science signals.
Search once, then narrow by source or topic.
<a href="https://www.fiercebiotech.com/pharma/novos-shares-tumble-8-after-2-trial-misses-semaglutide-alzheimers-disease" hreflang="en">Novo shares tumble after 2 trial misses for semaglutide in Alzheimer's disease</a>
Novo Nordisk has come up short in two phase 3 trials of semaglutide as a treatment for Alzheimer’s disease. But perhaps the larger story associated with the unsurprisin...
Novo Nordisk's semaglutide misses in closely-watched Alzheimer’s trials
Novo Nordisk’s bet on semaglutide in Alzheimer’s disease was always a long shot, and like most long shots, it has missed the mark. The GLP-1 agonist failed to delay dis...
Novo’s semaglutide fails in phase III Alzheimer’s trials
Novo Nordisk A/S’ wild card bet that its GLP-1 receptor agonist semaglutide could be used to treat Alzheimer’s disease has not paid off, with the company reporting two...
Novo Nordisk’s GLP-1 misses goal in closely watched Alzheimer’s studies
The studies offer perhaps the most concrete rebuttal yet to an idea that GLP-1 drugs, which have profound benefits on weight loss and heart health, might also help comb...
Novo, Lilly begin to sell obesity medications directly to employers
Building on the growing success of offering cheaper cash-pay prices to consumers for their GLP-1 weight loss drugs, Novo Nordisk and Eli Lilly are setting up programs t...
Biotechnology Market Therapeutic Innovations & Forecast Report 2025-2033 Featuring Lonza, Amgen, Syngenta, Biocon, Biogen, F. Hoffmann-La Roche, Novartis, Novo Nordisk A/S, Pfizer, and Seagen - ResearchAndMarkets.com - Business Wire
Biotechnology Market Therapeutic Innovations & Forecast Report 2025-2033 Featuring Lonza, Amgen, Syngenta, Biocon, Biogen, F. Hoffmann-La Roche, Novartis, Novo Nordisk...
Brand directory, kept in view
A rolling strip of the companies, platforms, CROs and device makers that show up across the coverage.
Open about page